Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ICU
$2.38
$
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
Next Earnings
2026-02-25
Beta
-0.981
Average Volume
Market Cap
Last Dividend
CIK
0001831868
ISIN
US81256L3024
CUSIP
81256L302
CEO
Eric Schlorff
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
19
IPO Date
2021-03-18
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| ICU Medical to Participate in Upcoming Investor Conferences | SAN CLEMENTE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences: | GlobeNewsWire | 2026-02-23 08:30:00 |
| ICU Medical Announces Fourth Quarter 2025 Results and Provides Fiscal Year 2026 Guidance | SAN CLEMENTE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended December 31, 2025. | GlobeNewsWire | 2026-02-19 16:05:00 |
| SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI) | Strong survival data extending to 90 days Real-world experience shows results consistent with clinical trial data Favorable safety profile – no device-related adverse events DENVER, Feb. 09, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today the publication of early post-approval clinical experience from the use of the QUELIMMUNE (Selective Cytopheretic Device for Pediatrics, or SCD-PED) therapy in the prestigious, peer-reviewed journal Pediatric Nephrology . The publication, co-authored by leading experts including Stuart Goldstein, Kelli Krallman, Meredith Harris, Rajit Basu, David Askenazi, Shina Menon, Matt Zinter, Steven Gorga, and H. | GlobeNewsWire | 2026-02-09 08:20:00 |
| ICU Medical Announces Time of Fourth Quarter 2025 Earnings Conference Call | SAN CLEMENTE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2025 earnings release and conference call. | GlobeNewsWire | 2026-02-05 08:30:00 |
| SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference | DENVER, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on Thursday, February 5th at 11:30 am Eastern Time. | GlobeNewsWire | 2026-01-29 08:25:00 |
| VSee and DocBox Announce Strategic Partnership to Launch the First Augmented Intelligence Platform for Virtual ICU | Creating a scalable, AI‑native Virtual ICU platform that drives new recurring revenue and enterprise value. SAN JOSE, CALIFORNIA / ACCESS Newswire / January 29, 2026 / VSee Health, Inc. (Nasdaq:VSEE), a leader in enterprise telehealth and AI-powered virtual care, today announced a strategic partnership with DocBox, the first Augmented Intelligence platform for critical care, to create a next-generation Virtual ICU operating system for hospitals worldwide. | Accesswire | 2026-01-29 08:11:00 |
| "Fiat in ICU": Mark Thornton on the silver supply crisis & 2026 crash signals | Jeremy Szafron joins Kitco News as an anchor and producer from Kitco's Vancouver bureau. Jeremy is a seasoned journalist with a diverse background covering entertainment, current affairs and finance. | Kitco | 2026-01-21 10:45:03 |
| SeaStar Medical Announces 2026 Milestones | Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer base Advance SeaStar Medical's first-in-class SCD therapy for the adult AKI indication – a potential $4.5 billion market – through completion of enrollment of the NEUTRALIZE-AKI pivotal trial and initiation of the PMA process Progress the clinical development of the SCD therapy in patients with severe heart failure Leverage rapid pathways to commercialization of the SCD therapy through additional FDA Humanitarian Use and Breakthrough Device Designations DENVER, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today its key milestones for 2026. “Our first full year as a commercial company provided a clear demonstration that the Selective Cytopheretic Device (SCD) therapy can save lives and spare organ function, with major pediatric medical institutions, such as Cincinnati Children's Hospital, Stanford Medical Center, UCSF Benioff Children's Hospitals, and University of Michigan, adopting the therapy and reporting their findings,” said Eric Schlorff, CEO of SeaStar Medical. | GlobeNewsWire | 2026-01-07 08:13:00 |
| SeaStar Medical to Present at Upcoming Biotech Showcase 2026 Investor Conference | DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at the Biotech Showcase 2026 Investor Conference at the Hilton Union Square, San Francisco, CA, on January 13, 2026, at 3:00 p.m. Pacific Standard Time. | GlobeNewsWire | 2026-01-06 08:53:00 |
| ICU Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference | SAN CLEMENTE, Calif., Dec. 31, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the 44th Annual J.P. | GlobeNewsWire | 2025-12-31 08:30:00 |
| ICU Medical: Difficult Transition, A More Interesting Company (Upgrade) | ICU Medical has emerged from a painful post-Smiths Medical integration process, shifting focus from remediation to growth and margin expansion. Essentially divesting the low-margin IV solutions business to Otsuka and launching new products can drive gross margin improvement toward 43%-45%. ICUI should achieve sustained EBITDA margins above 20% and double-digit FCF growth, supporting deleveraging and potential capital returns. | Seeking Alpha | 2025-12-30 17:31:11 |
| SeaStar Medical Announces 1-for-10 Reverse Split | DENVER, Dec. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today the Company's 1-for-10 reverse stock split (Reverse Split), which will become effective as of 12:01 a.m. Eastern Time on January 5, 2026. The Company's common stock will begin trading on a post-split adjusted basis on The Nasdaq Capital Market (Nasdaq) effective with the open of the market on January 5, 2026. SeaStar Medical's stock will continue to trade under the ticker symbol “ICU.” | GlobeNewsWire | 2025-12-23 16:25:00 |
| SeaStar Medical Announces FDA Approval of Reduction in Mandatory Enrollment for SAVE Surveillance Registry Evaluating QUELIMMUNE™ Safety for Pediatric AKI | FDA lowers surveillance requirement to 50 patients from 300 patients in original HDE approval based on assessment of first 21 SAVE Surveillance Registry patients | GlobeNewsWire | 2025-12-02 08:27:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| 4 | 2026-02-10 | 2026-02-10 | View Filing |
| 4 | 2026-02-10 | 2026-02-10 | View Filing |
| 4 | 2026-02-10 | 2026-02-10 | View Filing |
| 4 | 2026-02-10 | 2026-02-10 | View Filing |
| 4 | 2026-02-10 | 2026-02-10 | View Filing |
| 4 | 2026-02-10 | 2026-02-10 | View Filing |
| 4 | 2026-02-10 | 2026-02-10 | View Filing |
| 8-K | 2026-01-20 | 2026-01-20 | View Filing |
| 8-K/A | 2025-12-23 | 2025-12-23 | View Filing |
| 4 | 2025-12-22 | 2025-12-22 | View Filing |
| 8-K | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-11 | 2025-12-11 | View Filing |
| 3 | 2025-12-08 | 2025-12-08 | View Filing |
| 424B5 | 2025-11-20 | 2025-11-20 | View Filing |
| 8-K | 2025-11-17 | 2025-11-17 | View Filing |
| DEF 14A | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| SC 13G/A | 2025-11-07 | 2025-11-07 | View Filing |
| PRE 14A | 2025-11-04 | 2025-11-04 | View Filing |
| 424B5 | 2025-10-14 | 2025-10-14 | View Filing |
| 8-K | 2025-09-29 | 2025-09-29 | View Filing |
| 8-K | 2025-09-24 | 2025-09-24 | View Filing |
| 3 | 2025-09-09 | 2025-09-09 | View Filing |
| 4 | 2025-08-28 | 2025-08-28 | View Filing |
| 4 | 2025-08-25 | 2025-08-25 | View Filing |
| 8-K | 2025-08-19 | 2025-08-19 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K/A | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-08-13 | 2025-08-13 | View Filing |
| SC 13G/A | 2025-08-13 | 2025-08-13 | View Filing |
| EFFECT | 2025-08-13 | 2025-08-13 | View Filing |
| S-1 | 2025-08-08 | 2025-08-08 | View Filing |
| 8-K | 2025-08-08 | 2025-08-08 | View Filing |
| 424B5 | 2025-08-08 | 2025-08-08 | View Filing |
| S-8 | 2025-08-08 | 2025-08-08 | View Filing |
| 8-K/A | 2025-08-06 | 2025-08-05 | View Filing |
| 8-K | 2025-08-06 | 2025-08-05 | View Filing |
| 8-K | 2025-08-01 | 2025-08-01 | View Filing |
| 424B5 | 2025-08-01 | 2025-08-01 | View Filing |
| 4 | 2025-07-16 | 2025-07-16 | View Filing |
| 4 | 2025-07-16 | 2025-07-16 | View Filing |
| 4 | 2025-07-16 | 2025-07-16 | View Filing |
| 4 | 2025-07-16 | 2025-07-16 | View Filing |
| 8-K | 2025-07-16 | 2025-07-16 | View Filing |
| 8-K | 2025-07-14 | 2025-07-14 | View Filing |
| 424B5 | 2025-07-11 | 2025-07-11 | View Filing |
| 424B5 | 2025-07-10 | 2025-07-10 | View Filing |
| 8-K | 2025-07-08 | 2025-07-08 | View Filing |
| 4 | 2025-07-03 | 2025-07-03 | View Filing |
| 4 | 2025-07-03 | 2025-07-03 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 8-K | 2025-07-02 | 2025-07-02 | View Filing |
| SC 13G | 2025-06-27 | 2025-06-27 | View Filing |
| 4 | 2025-06-27 | 2025-06-27 | View Filing |
| 424B4 | 2025-06-23 | 2025-06-23 | View Filing |
| 8-K | 2025-06-23 | 2025-06-23 | View Filing |
| EFFECT | 2025-06-23 | 2025-06-23 | View Filing |
| S-1/A | 2025-06-20 | 2025-06-20 | View Filing |
| S-1 | 2025-06-16 | 2025-06-16 | View Filing |
| 8-K | 2025-06-11 | 2025-06-11 | View Filing |
| 424B3 | 2025-05-29 | 2025-05-29 | View Filing |
| EFFECT | 2025-05-28 | 2025-05-28 | View Filing |
| 4 | 2025-05-22 | 2025-05-22 | View Filing |
| 4 | 2025-05-20 | 2025-05-20 | View Filing |
| S-1 | 2025-05-19 | 2025-05-19 | View Filing |
| SC 13G | 2025-05-15 | 2025-05-15 | View Filing |
| 10-Q | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| DEF 14A | 2025-05-06 | 2025-05-07 | View Filing |
| DEFA14A | 2025-05-06 | 2025-05-06 | View Filing |
| EFFECT | 2025-04-30 | 2025-04-30 | View Filing |
| PRE 14A | 2025-04-25 | 2025-04-25 | View Filing |
| 8-K | 2025-04-25 | 2025-04-25 | View Filing |
| 10-K/A | 2025-04-23 | 2025-04-23 | View Filing |
| S-3 | 2025-04-22 | 2025-04-22 | View Filing |
| S-8 | 2025-04-22 | 2025-04-22 | View Filing |
| 4 | 2025-04-03 | 2025-04-03 | View Filing |
| 4 | 2025-04-03 | 2025-04-03 | View Filing |
| 424B5 | 2025-04-02 | 2025-04-02 | View Filing |
| 8-K | 2025-03-28 | 2025-03-28 | View Filing |
| 10-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-03-21 | 2025-03-21 | View Filing |
| 8-K | 2025-03-13 | 2025-03-13 | View Filing |
| DEFR14A | 2025-03-04 | 2025-03-04 | View Filing |
| DEF 14A | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-27 | 2025-02-27 | View Filing |
| PRE 14A | 2025-02-18 | 2025-02-18 | View Filing |
| SC 13G/A | 2025-02-13 | 2025-02-13 | View Filing |
| 424B5 | 2025-02-03 | 2025-02-03 | View Filing |
| 8-K | 2025-02-03 | 2025-02-03 | View Filing |
| 8-K | 2025-01-31 | 2025-01-31 | View Filing |
| 8-K | 2025-01-13 | 2025-01-13 | View Filing |
| 8-K | 2024-12-26 | 2024-12-26 | View Filing |
| 8-K | 2024-12-19 | 2024-12-19 | View Filing |
| 3 | 2024-12-03 | 2024-12-03 | View Filing |
| 4 | 2024-12-03 | 2024-12-03 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Neural Forcast | 35.90% | 1.1 | 20 | 0.79 | 2.41 | 57.26 |
| Swarm Intelligence Strategy | 28.00% | 0.98 | 39 | 0.41 | 0.42 | 49.36 |
| Williams PercentR Strategy | 17.35% | 0.98 | 20 | 0.31 | 0.3 | 38.72 |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxx | xxxxxxxx% | xxxx | xx | xx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |